You are here

New Vaccine Candidate for Deadly H7N9 Flu Virus

Thirty-one deaths reported in China (May 8)

A new virus-like particle (VLP) vaccine candidate has been produced for the avian influenza A (H7N9) virus that is responsible for the current deadly flu outbreak in China.

In order to produce an influenza vaccine, the manufacturer — Medicago Inc., based in North Carolina and Canada — requires only the genetic sequence of the viral strain, thus limiting the delays that can occur using traditional manufacturing systems. Manufacturers of current egg-based flu vaccines can take up to 6 months to produce a vaccine for any new strain.

The new H7N9 VLP vaccine is currently being purified in preparation for immunogenicity studies in animal models.

To date, a total of 130 laboratory-confirmed cases of human infection with the H7N9 virus strain, including 31 deaths, have been reported to the World Health Organization (WHO).

Source: Medicago Inc.; May 8, 2013.

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs